Biocon announces positive phase I study results for biosimilar insulin Glargine

Biocon, Indian biotechnology company, announced positive results from a Phase I comparative study conducted in Germany of its Biosimilar Insulin Glargine in Type 1 Diabetes Mellitus (T1DM) patients.

This randomized, double-blind, euglycemic clamp study was conducted in T1DM patients to evaluate pharmacokinetic (PK) and  pharmacodynamic (PD) equivalence of Biocon’s Insulin Glargine against the innovator product (Lantus). The trial met all its primary and secondary endpoints.

These results indicate that Biocon’s Insulin Glargine is equivalent to the innovator product in terms of PK and PD. These robust clinical data along with extensive physicochemical and biological characterization data generated to date between Biocon’s Insulin Glargine and the innovator product will enable Biocon to start its Phase 3 program in the U.S. and E.U. aimed at demonstrating comparative safety, efficacy and immunogenicity in diabetes mellitus patients.

“This study clearly demonstrates that Biocon’s Insulin Glargine is bioequivalent to Lantus, so that both insulins will have the same effect when used in identical doses”, said Dr Tim Heise, CEO Science & Administration of Profil® in Neuss, Germany, and Principal Investigator of the study. “The study had a robust design, was conducted under the international standards of ICH/GCP (International Conference of Harmonization/Good Clinical Practice) and used an automated euglycemic glucose clamp technique which is the gold standard for assessment of the pharmacodynamic properties of insulin preparations. Biocon’s Insulin Glargine and LANTUS®
were very well tolerated; without any serious adverse event observed during the four month study period. I am very confident that based on these data, regulators will accept the pharamcokinetic and pharmacodynamic biosimilarity of Biocon’s Insulin Glargine and
Lantus.”

Expressing her satisfaction with the clinical development progress Ms. Kiran MazumdarShaw, Chairman & Managing Director, Biocon said, “Insulin Glargine is a key product in our growing portfolio of biosimilar insulins. The successful outcome of this critical Phase 1 study demonstrates our strong commitment towards developing high quality biosimilars and paves the way for the Phase 3 program of Biosimilar Insulin Glargine that will enable regulatory approvals of our product across developed and emerging markets. These data will further increase the confidence of physicians prescribing Basalog and contribute to our vision to have market leadership in biosimilar products.” 

Biocon intends on conducting the Phase 3 global program using internal resources and will be engaging with several potential regional and global partners to ensure affordable innovation is accessible to all patients across the globe.

Source: Biocon press release